Instil Bio, Inc. (TIL): R&D Expense
$24.74M
Year ended 2025-12-31
$13.56M
Trailing 12 months to 2026-06-30
-44.0%
3-year compound annual growth
+5.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.74M | +109.0% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $11.84M | -70.1% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $39.60M | -71.9% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $141.06M | +31.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $107.25M | +452.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $19.40M | n/a | 2022-03-07, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 2025-12-31 | $24.74M | +109.0% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $42.63M | +34.5% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $176.06M | -12.4% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $55.97M | +32.2% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $94.48M | +146.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
Compare TIL, TARA, NMRA, CMPX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗